Search Results - Retina Today

Sort By:

Relevance Date

Relevance

Date

March 2025 Supplement

Real World Experiences With C3 Complement Inhibition Treatment for GA

Jeff Heier, MD

July/August 2015 | Departments

5Q With David Eichenbaum, MD

David Eichenbaum, MD, is a Partner at Retina Vitreous Associates of Florida and an Affiliate Assistant Professor of Ophthalmology at the University of South Florida in Tampa, Florida.

September 2006

Clinical Trial Update: AMD

Trial: A Phase 4, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement